Olokizumab Proves Noninferior to Adalimumab for RA : compare

The manufacturer of olokizumab is expected to file for approval in the United States early next year, and the drug could add a new option for patients for whom methotrexate alone doesn't work.

Related Keywords

United States , Vienna , Wien , Austria , Russia , Josef Smolen , Paul Emery , Clinical Rheumatoid Arthritis Development For Olokizumab , American College Of Rheumatology , University Of Leeds England , University Of Vienna , New England Journal , Clinical Rheumatoid Arthritis Development , Medical University , American College , Disease Activity Score , Rheumatoid Arthritis , A , Drug Development , Temporal Arteritis , Giant Cell Arteritis , Vasculitis , Anti Tnf , Anti Tumor Necrosis Factor , Biologic Therapy , Receptors ,